Introduction: Hepatitis B is a significant public health problem.
Infected children <6 years represent a risk population of evolution to
chronicity. Objective: We aimed to assess newborns’ management and
outcome from reactive HBs Ag mothers at the El Rapha Polyclinic in Libreville,
Gabon. Methodology: Prospective longitudinal study, carried out over
four years, including all neonates born from reactive HBsAg mothers admitted in
the delivery room. The parameters studied were maternal age, gestation, marital
status, pregnancy follow-up, hepatitis B vaccination status, knowledge of
hepatitis B, anti-Hbc antibodies’ levels, HBeAg. For the newborn: term, birth
weight, management at birth, and hepatitis B serological status at 12 months. Results: We included 45 newborns. Mothers’ mean age was 30.9 ± seven years.
In 32.6% of cases, antenatal consultations were ≤4, and 9.3% were vaccinated
for hepatitis B. Mothers had chronic hepatitis in 74.4% of cases. All neonates
were vaccinated for hepatitis B at birth; 68.9% received hepatitis B
immunoglobulin. At 12 months, 77.8% had HBs antibody positive, and 6.7% were
HBsAg positive. Conclusion: Hepatitis B prevalence is significant among
parturients. It is essential to set up a national strategy for managing the
mother-child couple in a context of positive HBsAg.
References
[1]
Organisation mondiale de la santé (OMS) (2017) Rapports mondial sur l’hépatite.
https://www.who.int/hepatitis/publications/global-hepatitis-report2017executive..../fr
[2]
Organisation mondiale de la santé (OMS) (2019) Hépatite B, principaux faits.
https://www.who.int/fr/news-room/fact-sheets/detail/hepatitis-b
[3]
McMahon, B.J. (2010) Natural History of Chronic Hepatitis B. Clinical Liver Disease, 14, 381-396. https://doi.org/10.1016/j.cld.2010.05.007
[4]
MacLachlan, J.H., Locarnini, S. and Cowie, B.C. (2015) Estimating the Global Prevalence of Hepatitis B. The Lancet, 386, 1515-1517.
https://doi.org/10.1016/S0140-6736(15)61116-3
[5]
Masserey, S.V., Aebi, C., Matter, L., Boulvain, M. and Bucher, H.U. (2007) Recommandations pour la prévention de la transmission mère-enfant de l’hépatite B. Paediatrica, 18, 21-26.
[6]
Franco, E., Bagnato, B., Marino, M.G., Meleleo, C., Serino, L. and Zaratti, L. (2012) Hepatitis B: Epidemiology and Prevention in Developing Countries. World Journal of Hepatology, 4, 74-80. https://doi.org/10.4254/wjh.v4.i3.74
[7]
Office fédéral de la santé publique (OFSP) et Commission fédérale pour les vaccinations (CFV) (2019) Recommandations pour la prévention de l’hépatite B. Directives et recommandations. OFSP, Berne.
[8]
El Agheb, M.O.M. and Grange, J.D. (2015) Prévention de la transmission mère-enfant de l’hépatite B. The Pan African Medical Journal, 20, Article No. 316.
http://www.panafrican-med-journal.com/content//article/20/316/full
https://doi.org/10.11604/pamj.2015.20.316.6193
[9]
Rivet, C. and Broué, P. (2012) Hépatite virale B—Pas à Pas en Pédiatrie 2012.
[10]
Kasia, J.M., Noa Ndoua, C.C., Kensoung, H. and Belinga, E. (2020) Aspects cliniques et pronostiques de l’Hépatite Virale B en Grossesse au CHRACERH. Health Sciences and Disease, 21, 1-4. https://www.hsd-fmsb.org
[11]
Bigna, J.J.R., Noubiap, J.J.N., Nansseu, J.R.N. and Fokom-Domgue, J. (2015) Prevalence, Infectivity and Correlates of Hepatitis B Virus Infection among Pregnant Women in a Rural District of the Far North Region of Cameroon. BMC Public Health, 15, 454. https://doi.org/10.1186/s12889-015-1806-2
[12]
Sidibé, S., Sacko, B.Y. and Traoré, I. (2001) Prévalence des marqueurs sérologiques du virus de l’hépatite B chez les femmes enceintes dans le district de Bamako, Mali. Bulletin de la Société de Pathologie Exotique, 94, 339-341.
[13]
Sangaré, L., Sombié, R., Combasséré, A.W., Kouanda, A., Kania, D., Zerbo, O., et al. (2009) Transmission anténatale du virus de l’hépatite B en zone de prévalence modérée du VIH, Ouagadougou, Burkina Faso. Bulletin de la Société de Pathologie Exotique, 102, 226-229.
[14]
Mansour, W., Malick, F.Z., Sidiya, A., Ishagh, E., Chekaraou, M.A., Veillon, P., et al. (2012) Prevalence, Risk Factors, and Molecular Epidemiology of Hepatitis B and Hepatitis Delta Virus in Pregnant Women and in Patients in Mauritania. Journal of Medical Virology, 84, 1186-1198. https://doi.org/10.1002/jmv.23336
[15]
Sbiti, M., Khalki, H., Benbella, I. and Louzi, L. (2016) Séroprévalence de l’HBsAg chez la femme enceinte dans le centre du Maroc. The Pan African Medical Journal, 24, 187. https://doi.org/10.11604/pamj.2016.24.187.9849
[16]
Sellier, P., Maylin, S., Moreno, M., Ricbourg, A., Mazeron, M.C., Lopes, A., et al. (2013) Vertical Hepatitis b Virus Transmission Despite Serovaccination of the New-Born in Highly Viraemic Mono-Infected Mothers from Various Ethnic Origins: A Retrospective Study in Paris, France. Journal of Hepatology, 58, 63-67.
https://doi.org/10.1016/S0168-8278(13)60430-4
[17]
Makuwa, M., Caron, M., Souquière, S., Malonga-Mouelet, G., Mahé, A. and Kazanji, M. (2008) Prevalence and Genetic Diversity of Hepatitis B and Delta Viruses in Pregnant Women in Gabon: Molecular Evidence That Hepatitis Delta Virus Clade 8 Originates from and Is Endemic in Central Africa. Journal of Clinical Microbiology, 46, 754-756. https://doi.org/10.1128/JCM.02142-07
[18]
Groc, S., Abbate, J.L., Le Gal, F., Gerber, A., Tuaillon, E., Albert, J.L., et al. (2019) High Prevalence and Diversity of Hepatitis B and Hepatitis Delta Virus in Gabon. Journal of Viral Hepatitis, 26, 170-182. https://doi.org/10.1111/jvh.12991
[19]
Komas, N.P., Ghosh, S., Abdou-Chekaraou, M., Pradat, P., Al Hawajri, N., Manirakiza, A., et al. (2018) Hepatitis B and Hepatitis D Virus Infections in the Central African Republic, Twenty-Five Years after a Fulminant Hepatitis Outbreak, Indicate Continuing Spread in Asymptomatic Young Adults. PLOS Neglected Tropical Diseases, 12, e0006377. https://doi.org/10.1371/journal.pntd.0006377
[20]
Mansour, W. (2012) Prévalence et diversité génétique des souches HBV et HDV circulant au Niger et en Mauritanie. Microbiologie et Parasitologie. Université d’Angers. https://tel.archives-ouvertes.fr/tel-00991555
[21]
Pourette, D. and Enel, C. (2014) Représentations et vécu de l’hépatite B de patients subsahariens en Côte d’Ivoire et en France. Santé publique, 26, 869-878.
https://doi.org/10.3917/spub.146.0869
[22]
Organisation Mondiale de la Santé (OMS) (2012) Prévention et lutte contre l’hépatite virale: Cadre pour l’action mondiale. Genève.
http://apps.who.int/iris/bitstream/10665/130013/1/WHO_HSE_PED_HIP_GHP_2012.1_fre.pdf?ua=1&ua=1
[23]
Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G. and Ott, J.J. (2015) Estimations of Worldwide Prevalence of Chronic Hepatitis B Virus Infection: A Systematic Review of Data Published between 1965 and 2013. The Lancet, 386, 1546-1555.
https://doi.org/10.1016/S0140-6736(15)61412-X
[24]
Antona, D. (2006) L’hépatite B en France: Aspects épidémiologiques et stratégie vaccinale. Hepato-Gastro, 13, 51-61.
[25]
Meireles, L.C., Marinho, R.T. and Van Damme, P. (2015) Three Decades of Hepatitis B Control with Vaccination. World Journal of Hepatology, 7, 2127-2132.
https://doi.org/10.4254/wjh.v7.i18.2127
[26]
Zou, H. (2012) Virologic Factors Associated with Failure to Passive-Active Immunoprophylaxis in Infants Born to HBsAg-Positive Mothers. Journal of Viral Hepatitis, 19, 18-25. https://doi.org/10.1111/j.1365-2893.2011.01492.x
[27]
Souquière, S.F., Makuwa, M., Bisvigou, U. and Kazanji, M. (2016) Epidemiological and Molecular Features of Hepatitis B and Hepatitis Delta Virus Transmission in a Remote Rural Community in Central Africa. Infection, Genetics and Evolution, 39, 12-21. https://doi.org/10.1016/j.meegid.2015.12.021
[28]
Enquête Démographique et de Santé du Gabon 2012: Rapport de synthèse.
https://gabon.unfpa.org/sites/default/files/pub-pdf/EDS%20II%20-%20RAPPORT%20DE%20SYNTHESE.pdf
[29]
Lemoine, M., Girard, P.M., Thursz, M. and Raguin, G. (2013) Dans l’ombre du VIH/ SIDA: Les maladies oubliées de l’Afrique sub-saharienne. Quels enjeux sanitaires? Quelle responsabilité des bailleurs de fonds? Face à face. 12.
http://faceaface.revues.org/792
[30]
Hépatites en Afrique. L’appel de Dakar 2011.
http://www.hepatitesafrique.org/index.php/l-initiative/l-appel-de-dakar
[31]
Hépatites en Afrique. Conférence internationale des acteurs de lutte contre les hépatites en Afrique: Le consensus de Dakar 2013, Dakar (Sénégal).
http://www.hepatitesafrique.org/images/docs/consensus/declaration.pdf
[32]
Gkouvatsos, K., Goossens, N., Spahr, L. and Negro, F. (2017) Hépatite B: Nouvelles recommandations de prise en charge. Revue Médicale Suisse, 13, 1458-1463.
[33]
Schillie, S., Vellozzi, C., Reingold, A., et al. (2018) Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recommendations and Reports, 67, 1-31.
https://doi.org/10.15585/mmwr.rr6701a1
[34]
European Centre for Disease Prevention and Control (2017) Antenatal Screening for HIV, Hepatitis B, Syphilis, and Rubella Susceptibility in the EU/ EEA—Addressing the Vulnerable Populations. ECDC, Stockholm.
[35]
Brown, R.S., McMahon, B.J., Lok, A.S.F., et al. (2016) Antiviral Therapy in Chronic Hepatitis B Viral Infection during Pregnancy: A Systematic Review and Meta-Analysis. Hepatology, 63, 319-333. https://doi.org/10.1002/hep.28302
[36]
Dionne-Odom, J., Tita, A.T. and Silverman, N.S. (2016) Hepatitis B in Pregnancy Screening, Treatment, and Prevention of Vertical Transmission. American Journal of Obstetrics and Gynecology, 214, 6-14. https://doi.org/10.1016/j.ajog.2015.09.100
[37]
Del Canho, R., Grosheide, P.M., Mazel, J.A., et al. (1997) Ten-Year Neonatal Hepatitis B, Vaccination Program, The Netherlands, 1982-1992: Protective Efficacy and Long-Term Immunogenicity. Vaccine, 15, 1624-1630.
https://doi.org/10.1016/S0264-410X(97)00080-7
